SBIR-STTR Award

Circulating Prostate Cancer Progenitor Cell Assay Development
Award last edited on: 9/5/2014

Sponsored Program
STTR
Awarding Agency
DOD : Army
Total Award Amount
$844,318
Award Phase
2
Solicitation Topic Code
A08-T041
Principal Investigator
Michael Zwick

Company Information

AndroBioSys Inc

Elm and Carlton Streets
Buffalo, NY 14263
   (716) 845-8226
   mzwick@androbiosys.com
   www.androbiosys.com

Research Institution

Roswell Park Cancer Institute

Phase I

Contract Number: W81XWH-08-C-0099
Start Date: 7/10/2008    Completed: 2/28/2009
Phase I year
2008
Phase I Amount
$96,765
This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate progenitor cells. The eventual goal of this work would be to develop a high throughput blood-based assay highly specific for circulating prostate cancer progenitor cells. A cell shed from a tumor must be capable of surviving separate from the microenvironment of the primary tumor, and possess the capacities of proliferation and plasticity, to regenerate a metastasis. These traits essentially describe a cancer stem cell (CSC). Therefore, we propose to develop a technology to identify circulating CSCs, or more accurately the progenitor cells that are their immediate progeny, an approach that should provide a more informative prognostic tool for prediction of aggressiveness and metastatic potential.

Keywords:
Cancer Stem Cells, Metastatic Prostate Cancer, Cancer Biomarkers

Phase II

Contract Number: W81XWH-08-C-0099
Start Date: 8/4/2010    Completed: 10/1/2012
Phase II year
2008
Phase II Amount
$747,553
The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cells. We propose to utilize the information from the Phase I award and subsequent research to develop assay reagents that would be used to develop a blood-based assay specific for circulating prostate cancer stem cells. This assay should prove to be an informative prognostic tool for predicting aggressiveness and metastatic potential of prostate cancer.

Keywords:
CANCER STEM CELLS, METASTATIC PROSTATE CANCER, CANCER BIOMARKERS